Study of JDB0131 for drug-resistant TB
Treatments studied
Part of Infections clinical trials.
This trial tests a new tablet called JDB0131 for people with tuberculosis (TB) that is resistant to the antibiotic rifampicin. The goal is to see if it can effectively treat this hard-to-treat form of TB.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 14 and 65 years old.
- You weigh between 40 and 90 kilograms.
- You have active TB that is resistant to the antibiotic rifampicin (confirmed by lab tests within the last 3 months).
- Your sputum test shows TB bacteria (moderate or higher on two tests, or high on one and moderate on another).
- If you are currently on TB treatment, you are willing to stop and have a 7-day break before starting the study drug.
- You agree to use effective birth control during the study and for 6 months after stopping the drug (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new “triple-dose” set of medicines to treat people whose tuberculosis (TB) has come back in the lungs. If you qualify, the goal is to improve cure rates and reduce the chance of TB returning again.
This trial tests a three-drug combination (bedaquiline, delamanid, and linezolid) to see if it's safe and works well for people with multi-drug resistant or rifampicin-resistant tuberculosis. It may offer a new treatment option if standard drugs aren't working.
This study is testing new combinations of drugs to treat tuberculosis (TB) in the lungs. It aims to find a more effective and shorter treatment, and you may benefit from receiving these new drugs while helping advance TB research.
This trial tests a combination of drugs for people with active tuberculosis who have not been treated before. It aims to find a better way to treat TB, even if the bacteria are resistant to some drugs.
This trial tests a shorter treatment for drug-resistant tuberculosis (TB) using the medicine Pretomanid. It aims to find a more manageable cure for people whose TB does not respond to the standard first-line drug, rifampicin.
This Phase 2 study tests treatment for people with newly diagnosed, drug-susceptible pulmonary (lung) tuberculosis (TB). It aims to see whether the study treatment works well and is safe for curing TB.
Hear when a new Tuberculosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.